Table 2.
Demographic, HIV-related factors, and mortality causes of cases that died in the first year after TE diagnosis by study group
| 1992–1994N = 87 | 1995–1997N = 67 | 1998–2008N = 35 | |
|---|---|---|---|
| Male (%) | 73.6 | 76.1 | 65.7 |
| Age at death M (IQR) | 34.4 (30.0–40.6) | 38.3 (33.3–43.0) | 39.4 (34.6–44.0)* |
| IDU antecedent (%) | 56.3 | 64.2 | 60.0 |
| Months AIDS-TE M (IQR) | 0.0 (0.0–2.0) | 0.0 (0.0–0.8) | 0.2 (0.0–7.5)** |
| CD4 cell < 200/μL at TE (%) | 90.5 | 90.0 | 90.9 |
| TE prophylaxis (%) | 46.0 | 65.7 | 68.5** |
| HAART (%) | 0 | 4.5 | 28.6** |
| Death causes (%) | |||
| Cardiovascular conditions | 11.5 | 20.9 | 17.1 |
| Pulmonary conditions | 44.8 | 41.8 | 42.9 |
| Gastrointestinal conditions | 12.6 | 4.5 | 8.6 |
| Metabolic conditions | 6.9 | 10.4 | 8.6 |
| Neurological conditions | 17.2 | 14.9 | 11.4 |
| Sepsis | 6.9 | 16.4 | 25.7** |
| PJP | 6.9 | 6.0 | 0 |
| TE | 57.5 | 53.7 | 48.6 |
| KS | 5.7 | 1.5 | 2.9 |
*
P < 0.01 between years groups.
**
P < 0.05 between years groups.
HIV = human immunodeficiency virus; TE = toxoplasmic encephalitis; M (IQR) = median interquartile rate; IDU = injecting drug use; AIDS = acquired immunodeficiency syndrome; HAART = highly active antiretroviral therapy; PJP = Pneumocystic jirovecii pneumonia; KS = Kaposi sarcoma.